keyword
MENU ▼
Read by QxMD icon Read
search

Advanced Renal cell carcinoma

keyword
https://www.readbyqxmd.com/read/29774766/negative-prognostic-factors-and-resulting-clinical-outcome-in-patients-with-metastatic-renal-cell-carcinoma-included-in-the-italian-nivolumab-expanded-access-program
#1
Sergio Bracarda, Luca Galli, Marco Maruzzo, Giovanni Lo Re, Sebastiano Buti, Adolfo Favaretto, Francesco Di Costanzo, Cosimo Sacco, Marco Merlano, Claudia Mucciarini, Elena Zafarana, Sante Romito, Antonio Maestri, Carmelo G Giorgio, Maria T Ionta, Daniele Turci, Ugo De Giorgi, Giuseppe Procopio, Enrico Cortesi, Diana Giannarelli, Camillo Porta
AIM: We report the outcomes observed with nivolumab in metastatic renal cell carcinoma patients with poor prognostic features enrolled in the Italian expanded access program. PATIENTS & METHODS: Nivolumab was available for patients who relapsed after at least one prior systemic treatment in the advanced or metastatic setting. RESULTS: Of 389 patients, 32 (8%) had brain metastasis, 129 (33%) had liver and 193 (50%) had bone metastasis. These subpopulations achieved a disease control rate of 53, 45 and 47%, respectively...
May 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/29767316/-ceus-diagnosis-of-solid-renal-tumors
#2
REVIEW
K Stock, H Kübler, T Maurer, J Slotta-Huspenina, K Holzapfel
CLINICAL ISSUE: Renal lesions are detected earlier, often as a result of ultrasound examinations. However, the imaging-based differential diagnosis of different tumour entities remains challenging STANDARD RADIOLOGICAL METHODS: All renal tumours >1 cm should be evaluated for malignancy by computed tomography (CT) or magnetic resonance imaging (MRI). If an angiomyolipoma diagnosis cannot be established with imaging, further diagnostics are appropriate or if malignant progression is suspected, then multidisciplinary discussion for TNM-staging based uro-oncologic therapy is usual...
May 16, 2018: Der Radiologe
https://www.readbyqxmd.com/read/29765173/hemodiafiltration-and-plasma-levels-of-axitinib-in-a-patient-with-metastatic-renal-clear-cell-carcinoma
#3
Jindrich Kopecky, Alena Ticha, Hana Janeckova, Melichar Bohuslav
BACKGROUND: The standard treatment for metastatic renal cancer is based on vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTor) inhibitors. Compared to other advanced tumors, the treatment of renal cancer is highly affected by impaired renal function; therefore, patients with severe renal insufficiency, including patients on hemodialysis, are generally excluded from clinical trials. CASE REPORT: In the present manuscript we present the case of a renal cancer patient who underwent bilateral nephrectomy and received two lines of treatment...
May 15, 2018: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/29762256/computed-tomography-perfusion-measurements-in-renal-lesions-obtained-by-bayesian-estimation-advanced-singular-value-decomposition-deconvolution-maximum-slope-and-patlak-models-intermodel-agreement-and-diagnostic-accuracy-of-tumor-classification
#4
Dominik Deniffel, Timothé Boutelier, Aissam Labani, Mickael Ohana, Daniela Pfeiffer, Catherine Roy
OBJECTIVES: The aims of this study were to evaluate the agreement of computed tomography (CT)-perfusion parameter values of the normal renal cortex and various renal tumors, which were obtained by different mathematical models, and to evaluate their diagnostic accuracy. MATERIALS AND METHODS: Perfusion imaging was performed prospectively in 35 patients to analyze 144 regions of interest of the normal renal cortex and 144 regions of interest of renal tumors, including 21 clear-cell renal cell carcinomas (RCC), 6 papillary RCCs, 5 oncocytomas, 1 chromophobe RCC, 1 angiomyolipoma with minimal fat, and 1 tubulocystic RCC...
May 14, 2018: Investigative Radiology
https://www.readbyqxmd.com/read/29760557/uca1-promotes-cell-proliferation-and-invasion-and-inhibits-apoptosis-through-regulation-of-the-mir129-sox4-pathway-in-renal-cell-carcinoma
#5
Qian Liu, Yang Li, Weiling Lv, Guangwei Zhang, Xin Tian, Xiaodong Li, Hepeng Cheng, Chaoyang Zhu
Background: Renal cell carcinoma (RCC) is the most common cancer in kidney malignancies. UCA1 has been identified as an oncogenic lncRNA in multiple cancers, including RCC. However, the underlying molecular mechanism of UCA1 involved in RCC progression is far from being addressed. Methods: Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) assays were used to measure expressions of UCA1, miR129, and SOX4 mRNA. Western blot assays were employed to detect SOX4 protein expression...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29757575/prognostic-role-of-preoperative-albumin-to-globulin-ratio-in-predicting-survival-of-clear-cell-renal-cell-carcinoma
#6
Murat Yavuz Koparal, Fazli Polat, Serhat Çetin, Ender Cem Bulut, Tevfik Sinan Sözen
PURPOSE: To investigate the prognostic role of preoperative albumin/globulin ratio (AGR) in predicting disease-free survival (DFS) and overall survival (OS) in localized and locally advanced clear cell renal cell carcinoma (RCC) patients. PATIENTS AND METHODS: 162 patients who met the criteria specified were included in the study. The DFS and OS ratios were determined using the Kaplan-Meier method. Univariate and multivariate Cox regression analyses were performed to determine the prognostic factors affecting DFS and OS...
May 5, 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29756394/prognostic-impact-of-the-pretreatment-aspartate-transaminase-alanine-transaminase-ratio-in-patients-treated-with-first-line-systemic-tyrosine-kinase-inhibitor-therapy-for-metastatic-renal-cell-carcinoma
#7
Minyong Kang, Jiwoong Yu, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Se Hoon Park, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Seong Il Seo
OBJECTIVES: To examine the prognostic role of the pretreatment aspartate transaminase/alanine transaminase or De Ritis ratio in patients with metastatic renal cell carcinoma receiving first-line systemic tyrosine kinase inhibitor therapy. METHODS: We retrospectively searched the medical records of 579 patients with metastatic renal cell carcinoma who visited Samsung Medical Center, Seoul, Korea, from January 2001 through August 2016. After excluding 210 patients, we analyzed 360 patients who received first-line tyrosine kinase inhibitor therapy...
May 13, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29755405/dual-paraneoplastic-endocrine-syndromes-heralding-onset-of-extrapulmonary-small-cell-carcinoma-a-case-report-and-narrative-review
#8
Jill B Feffer, Natalia M Branis, Jeanine B Albu
Objective: Extrapulmonary small cell carcinoma (EPSCC) is rare and frequent metastases at presentation can complicate efforts to identify a site of origin. In particular, SCC comprises <1% of prostate cancers and has been implicated in castration resistance. Methods: Clinical, laboratory, imaging, and pathology data are presented. Results: A 56-year-old man with locally advanced prostate adenocarcinoma on androgen deprivation therapy presented with a clogged nephrostomy tube...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29754934/comprehensive-genomic-profiling-of-metastatic-tumors-in-a-phase-2-biomarker-study-of-everolimus-in-advanced-renal-cell-carcinoma
#9
Xin Gao, Opeyemi Jegede, Connor Gray, Paul J Catalano, Jesse Novak, David J Kwiatkowski, Rana R McKay, Daniel J George, Toni K Choueiri, David F McDermott, Sabina Signoretti, Rupal S Bhatt
INTRODUCTION: Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC. We characterized the genomic profile of RCC tumors from metastatic sites and assessed whether particular alterations correlate with clinical response to everolimus. PATIENTS AND METHODS: An open-label, single-arm phase 2 biomarker study of everolimus 10 mg daily was conducted in metastatic RCC patients...
April 25, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29753244/renal-cell-carcinoma-in-one-year-going-inside-the-news-of-2017-a-report-of-the-main-advances-in-rcc-cancer-research
#10
REVIEW
Claudia Mosillo, Chiara Ciccarese, Davide Bimbatti, Emanuela Fantinel, Alberto Dalla Volta, Iolanda Bisogno, Ilaria Zampiva, Matteo Santoni, Francesco Massar, Matteo Brunelli, Rodolfo Montironi, Giampaolo Tortora, Roberto Iacovelli
Very interesting issues regarding RCC treatment have been raised during 2017. We analysed the main news that may potentially modified clinical practice. Conflicting data came from trials testing targeted therapies in the adjuvant setting, supporting the necessity of further investigations. One of the key goals of RCC research is focused on the first-line therapy, with particular interest focus on immunotherapy combinations. Redefine the standard of care with the aim of improving patients' survival represents an imperative need...
May 2, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29750962/long-noncoding-rna-cytor-in-cancer-a-tcga-data-review
#11
REVIEW
Jiayu Liang, Xin Wei, Zhihong Liu, Dehong Cao, Yongquan Tang, Zijun Zou, Chuan Zhou, Yiping Lu
BACKGROUND AND AIMS: Increasing evidence has shown the critical role of long non-coding RNA cytoskeleton regulator (CYTOR) in cancers. The expression of CYTOR is reported to be up-regulated in many kinds of cancers, such as gastric cancer, hepatocellular carcinoma, colon cancer, lung adenocarcinoma, oesophageal squamous cell carcinoma and renal cell carcinoma. Here, we summarized related studies and performed a meta-analysis to investigate the prognostic value of CYTOR in multiple cancers...
May 8, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29744074/peculiarities-and-management-challenges-of-advanced-renal-cell-carcinoma-incidentally-discovered-in-pregnancy
#12
Rotimi A David, Boluwatife Idowu, Cathlyn Akindiose, Adeyinka Laoye, John A Aluko, Adeleye D Omisore, Emmanuel Alajiki, Akinwumi O Komolafe, Abdulkadir A Salako, Uchenna Onwudiegwu
Our aim is that urologists, gynecologists, nephrologists, and general practitioners will be reminded that diagnosis of renal malignancies sometimes require a high index of suspicion as they may remain asymptomatic in advanced stages; even as they can also rarely co-exist with and cause peculiar challenges in pregnancy.
May 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29741507/cabozantinib-approved-for-first-line-treatment-of-advanced-renal-cell-carcinoma
#13
(no author information available yet)
No abstract text is available yet for this article.
February 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29740333/flavonoids-in-kidney-health-and-disease
#14
REVIEW
Félix Vargas, Paola Romecín, Ana I García-Guillén, Rosemary Wangesteen, Pablo Vargas-Tendero, M Dolores Paredes, Noemí M Atucha, Joaquín García-Estañ
This review summarizes the latest advances in knowledge on the effects of flavonoids on renal function in health and disease. Flavonoids have antihypertensive, antidiabetic, and antiinflammatory effects, among other therapeutic activities. Many of them also exert renoprotective actions that may be of interest in diseases such as glomerulonephritis, diabetic nephropathy, and chemically-induced kidney insufficiency. They affect several renal factors that promote diuresis and natriuresis, which may contribute to their well-known antihypertensive effect...
2018: Frontiers in Physiology
https://www.readbyqxmd.com/read/29737893/lenvatinib-for-the-treatment-of-kidney-cancer
#15
Hana Študentová, Denisa Vitásková, Bohuslav Melichar
Sequential administration of single targeted agents has evolved as the dominant paradigm in advanced RCC treatment. Lenvatinib plus everolimus is the first combination therapy in advanced RCC to show improvement in efficacy compared to monotherapy in advanced RCC while maintaining manageable toxicity profile. Areas covered: This review gives a brief overview of the contemporary clinical data on lenvatinib including its mechanism of action, pharmacokinetics, efficacy and safety profile in combination with everolimus...
June 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29736363/pushing-boundaries-robotic-nephrectomy-of-an-auto-transplanted-kidney-for-recurrent-renal-cell-carcinoma
#16
Belinda Li, Eric J Kirshenbaum, Parth Patel, Alex Gorbonos
Advances in robotic technology continue to expand the boundaries of minimally invasive approaches in transplant surgery. A single report has previously described the use of the robotic approach in transplant nephrectomy for a failed allograft. Our objective is to describe our technique and experience for the first reported robotic nephrectomy of an auto-transplanted solitary kidney for a recurrence of renal cell carcinoma (RCC). We highlight technical considerations during allograft mobilization and hilum dissection with the additional demands of a previously operated auto-transplant kidney...
March 6, 2018: Curēus
https://www.readbyqxmd.com/read/29728867/check-point-inhibitors-a-new-era-in-renal-cell-carcinoma-treatment
#17
REVIEW
Mohamed Alsharedi, Heather Katz
In the United States, the estimated number of new cases of renal cell carcinoma (RCC) is approximately 65,000 case with about 15,000 deaths in the year of 2018 (Siegel et al. in CA Cancer J Clin 68(1):7, 2018). RCC as an immunogenic malignancy is supported by many theories and facts which include tumor richness of lymphocytes infiltrate, the occurrence of spontaneous tumor regression, and the proved effect of traditional immunotherapy (Finke et al. in J Immunother 11(1):1-11, 1992), all these factors support the potential therapeutic effect of the novel immunotherapeutic agents in RCC...
May 4, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29728723/pushing-the-limits-of-immune-related-response-a-case-of-extreme-pseudoprogression
#18
Alvin S Wong, Yee-Liang Thian, Jeevesh Kapur, Cheng-Nang Leong, Patrick Kee, Chun-Tsu Lee, Martin B Lee
The advent of immune checkpoint targeted immunotherapy has seen a spectrum of immune-related phenomena in both tumor responses and toxicities. We describe a case of pseudoprogression that pushes the limits of immune-related response criteria and challenges the boundaries and definitions set by trial protocols. A middle-aged man with conventional clear cell renal cell carcinoma (RCC) had received multiple prior systemic treatments including vascular endothelial growth factor receptor tyrosine kinase inhibitors, as well as multiple surgeries and radiotherapy treatments...
May 4, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29726696/systematic-review-on-the-efficacy-and-safety-of-immune-checkpoint-inhibition-in-renal-cell-carcinoma
#19
Chen Lyu, Wenyue Li, Songcai Liu, Shuang Gao, Hong Zhang, Linlin Hao, Hao Yu, Wenzhen Wei, Jie Song, Yaoyao Yang, Chunmeng Wang, Zhimin Zhang, Nan Wang
To perform a systematic review of the relevant literature about clinical trials on efficacy and safety of immune checkpoint inhibition, whether it is used alone, in combination or with other targeted therapies in patients with advanced and metastatic renal cell carcinoma (RCC), two team members reviewed the abstracts and selected pertinent articles from the relevant databases. A narrative review of randomized controlled trials was performed and seven randomized controlled trials were identified in this systematic review...
May 4, 2018: Future Oncology
https://www.readbyqxmd.com/read/29725475/knockdown-of-long-non-coding-rna-pvt1-induces-apoptosis-and-cell-cycle-arrest-in-clear-cell-renal-cell-carcinoma-through-the-epidermal-growth-factor-receptor-pathway
#20
Weicong Li, Zaosong Zheng, Haicheng Chen, Yuhong Cai, Wenlian Xie
Previous years have witnessed the importance of long non-coding RNAs (lncRNAs) in cancer research. The lncRNA Pvt1 oncogene (non-protein coding) (PVT1) was revealed to be upregulated in various cancer types. The aim of the present study was to investigate the function of PVT1 in clear cell renal cell carcinoma (ccRCC). The expression of PVT1 in ccRCC was analyzed using reverse transcription-quantitative polymerase chain reaction, and it was revealed that PVT1 expression was upregulated in ccRCC tissues compared with that in normal adjacent tissues...
May 2018: Oncology Letters
keyword
keyword
65562
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"